- Home
- ACIU vs SRG Comparison
ACIU vs SRG Comparison
Compare ACIU & SRG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- SRG
- Stock Information
- Founded
- ACIU 2003
- SRG 2014
- Country
- ACIU Switzerland
- SRG United States
- Employees
- ACIU N/A
- SRG N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- SRG Real Estate Investment Trusts
- Sector
- ACIU Health Care
- SRG Real Estate
- Exchange
- ACIU Nasdaq
- SRG Nasdaq
- Market Cap
- ACIU 213.3M
- SRG 237.7M
- IPO Year
- ACIU 2016
- SRG 2015
- Fundamental
- Price
- ACIU $2.90
- SRG $4.06
- Analyst Decision
- ACIU Strong Buy
- SRG
- Analyst Count
- ACIU 2
- SRG 0
- Target Price
- ACIU $10.00
- SRG N/A
- AVG Volume (30 Days)
- ACIU 343.9K
- SRG 92.8K
- Earning Date
- ACIU 11-04-2025
- SRG 11-11-2025
- Dividend Yield
- ACIU N/A
- SRG N/A
- EPS Growth
- ACIU N/A
- SRG N/A
- EPS
- ACIU N/A
- SRG N/A
- Revenue
- ACIU $36,362,036.00
- SRG $15,346,000.00
- Revenue This Year
- ACIU N/A
- SRG N/A
- Revenue Next Year
- ACIU $1,022.98
- SRG N/A
- P/E Ratio
- ACIU N/A
- SRG N/A
- Revenue Growth
- ACIU 86.71
- SRG N/A
- 52 Week Low
- ACIU $1.43
- SRG $2.43
- 52 Week High
- ACIU $3.99
- SRG $4.72
- Technical
- Relative Strength Index (RSI)
- ACIU 47.76
- SRG 51.89
- Support Level
- ACIU $2.89
- SRG $3.88
- Resistance Level
- ACIU $3.21
- SRG $4.21
- Average True Range (ATR)
- ACIU 0.33
- SRG 0.17
- MACD
- ACIU -0.08
- SRG -0.04
- Stochastic Oscillator
- ACIU 3.95
- SRG 41.94
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About SRG Seritage Growth Properties
Seritage Growth Properties is principally engaged in the ownership, development, redevelopment, management, and leasing of diversified and mixed-use properties throughout the United States.